What is the half-life of Tirzepatide?
Tirzepatide has a reported half life of ~5 days, given subcutaneous. That is why it is typically dosed once weekly. A shorter half life means more frequent dosing to keep blood levels steady, a longer one lets you space doses further apart.
Quick facts
- Half-life: ~5 days
- Route: Subcutaneous
- Typical schedule: Once weekly
- Cycle length: Open-ended, titrate over months
References
- Tirzepatide Once Weekly for Treatment of Obesity (SURMOUNT-1) — Jastreboff AM et al., NEJM, 2022
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — Frías et al., N Engl J Med, 2021
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial — Garvey et al., Lancet, 2023
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Tirzepatide
Last updated 2026-06-06.